Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x100px
Organisation › Details

Kinaxo Biotechnologies GmbH

KINAXO is a spin-off from the Max Planck Institute of Biochemistry in Martinsried, initiated by Prof. Dr. Axel Ullrich and Dr. Henrik Daub as well as Garching Innovation GmbH, the technology transfer center of the Max Planck Society. KINAXO supports pharmaceutical and biotech companies in the development and optimization of so-called spectrum-specific kinase inhibitors. With the KinaTorTM technology, KINAXO has accessed an innovative proprietary platform that can be used for efficient and directed improvement of a drug lead's therapeutic characteristics *


Period Start 2006-03-01 splitoff (date ca.)
Period End 2018-12-13 renamed before
  Group Evotec (Group)
  Today Evotec (München) GmbH
  Predecessor Max Planck Institute for Biochemistry (MPIB) (Martinsried/Munich)
  Successor Evotec (München) GmbH
Products Industry drug discovery services
  Industry 2 KinAffinity® kinase inhibitor profiling services
Person Person Jenne, Andreas (RSP Systems 201805– CEO before NEO New Oncology + Blackfield + Kinaxo)
Region Region Martinsried
  Country Germany
  Street 19a Am Klopferspitz
  City 82152 Martinsried
  Tel +49-89-461-3363-0
    Address record changed: 2020-12-02
Basic data Employees B: 11 to 50 (2011-06-01)
    * Document for »About Section«: 
Record changed: 2023-12-30


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Evotec (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x300px

» top